Angiodynamics Inc (ANGO)

$12.68 -0.16 (-1.25%)
Market Cap 522.42M
Revenue (ttm) 292.50M
Net Income (ttm) -33.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -11.62%
Debt to Equity Ratio 0.00
Volume 357,900
Avg Vol 445,712
Day's Range N/A - N/A
Shares Out 41.20M
Stochastic %K 16%
Beta 0.47
Analysts Strong Sell
Price Target $19.33

Company Profile

AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company's thrombus management portfolio includes AlphaVac mechanical thrombectomy sy...

Industry: Medical Instruments & Supplies
Sector: Healthcare
Phone: 518 795 1400
Address:
14 Plaza Drive, Latham, United States
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 12:30 AM
$ANGO RSI: 40.91, MACD: 0.1206 Vol: 0.22, MA20: 13.26, MA50: 12.61 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RococoReturns
RococoReturns Dec. 25 at 11:43 AM
$ANGO The next leg of valuation movement will likely hinge on how management navigates competing priorities. The market is increasingly intolerant of delays that stretch credibility. Sharper prioritization may be required to avoid execution dilution. Sustainable upside exists, but only alongside disciplined follow‑through.
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 7:18 PM
$ANGO surges 30.2% in 6 months — what's driving the momentum? 🚀 🔬 NanoKnife sees 25% revenue growth in prostate cancer with expanding adoption 💉 Med Tech segment now nearly 50% of sales, led by 26% growth in Q1 📈 Thrombectomy revenue jumps 41.2% with aggressive market penetration Discover why ANGO is on the rise 👉 https://www.zacks.com/stock/news/2808804/reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2808804-body-26320&ADID=SYND_STOCKTWITS_TWEET_2_2808804_BODY_26320
1 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 6:18 PM
Still holding $ANGO? Here’s why that call isn’t crazy right now 👀 AngioDynamics continues to benefit from NanoKnife, ongoing clinical milestones, and a balanced portfolio, which are helping counter tariff headwinds and support a hold stance for the time being. Full hold-case breakdown here 👉 https://www.zacks.com/stock/news/2808804/reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2808804-teaser-26288&ADID=SYND_STOCKTWITS_TWEET_2_2808804_TEASER_26288
0 · Reply
Estimize
Estimize Dec. 18 at 11:03 PM
Wall St is expecting -0.10 EPS for $ANGO Q2 [Reporting 01/01 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
Estimize
Estimize Dec. 10 at 11:03 AM
Wall St is expecting -0.10 EPS for $ANGO Q2 [Reporting 01/01 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 7:14 PM
$ANGO Share Price: $13.38 Contract Selected: Jul 17, 2026 $12.5 Calls Buy Zone: $1.44 – $1.78 Target Zone: $2.41 – $2.94 Potential Upside: 57% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
buythedipanddonttrip
buythedipanddonttrip Dec. 5 at 3:51 PM
$ANGO Panagora Asset Management Inc. Sells 138,518 Shares of AngioDynamics, Inc. $ANGO
0 · Reply
Doozio
Doozio Nov. 24 at 6:17 PM
$ANGO Thursday 🐑 low???? 🍿. Bums.
0 · Reply
Doozio
Doozio Nov. 24 at 6:16 PM
$ANGO it can’t be a MNDY 🐑 suck in if all them bums been selling like scuuuured jabronis!
0 · Reply
Latest News on ANGO
AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Dec 30, 2025, 6:51 AM EST - 5 days ago

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

AngioDynamics: Growth Remains Under The Radar

Dec 29, 2025, 6:47 PM EST - 6 days ago

AngioDynamics: Growth Remains Under The Radar

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

Dec 23, 2025, 8:00 AM EST - 12 days ago

AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 22, 2025, 8:00 AM EST - 13 days ago

AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference

AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 10, 2025, 10:31 AM EST - 7 weeks ago

AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript

AngioDynamics to Participate in the UBS Global Healthcare Conference

Oct 27, 2025, 4:30 PM EDT - 2 months ago

AngioDynamics to Participate in the UBS Global Healthcare Conference

AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

Oct 13, 2025, 8:30 AM EDT - 2 months ago

AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List

AngioDynamics: Discounted Sales Multiple With Real Growth Engines

Oct 2, 2025, 3:00 PM EDT - 3 months ago

AngioDynamics: Discounted Sales Multiple With Real Growth Engines

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

Oct 2, 2025, 10:02 AM EDT - 3 months ago

AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

Oct 2, 2025, 9:44 AM EDT - 3 months ago

Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

Oct 2, 2025, 6:00 AM EDT - 3 months ago

AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum

Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

Oct 1, 2025, 9:57 AM EDT - 3 months ago

Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

Sep 18, 2025, 8:00 AM EDT - 3 months ago

AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025

AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul

Aug 17, 2025, 8:23 AM EDT - 5 months ago

AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 4:30 PM EDT - 5 months ago

AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

Jul 28, 2025, 8:30 AM EDT - 5 months ago

AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

Jul 23, 2025, 8:30 AM EDT - 5 months ago

AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

Jul 15, 2025, 12:40 PM EDT - 6 months ago

AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

Jul 15, 2025, 11:59 AM EDT - 6 months ago

AngioDynamics 'Exceptionally Well-Positioned' For 2026, CEO Says: But Tariffs Still Sting

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

Jul 15, 2025, 6:30 AM EDT - 6 months ago

AngioDynamics Reports Strong Fiscal Year 2025 Fourth Quarter and Full Year Financial Results; Continued Execution Driving Accelerated, Profitable Growth

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

Jul 7, 2025, 8:00 AM EDT - 6 months ago

AngioDynamics to Report Fiscal 2025 Fourth Quarter and Full-Year Financial Results on Tuesday, July 15, 2025

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

Jun 23, 2025, 8:00 AM EDT - 6 months ago

AngioDynamics Announces First Patient Enrolled in RECOVER-AV Clinical Trial Evaluating AlphaVac F1885 System for Treatment of Acute Pulmonary Embolism

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

Apr 2, 2025, 10:41 AM EDT - 9 months ago

Medical Device Maker AngioDynamics Stock Jumps On Better Than Expected Q3 Earnings, Upbeat Annual Guidance

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

Apr 2, 2025, 10:20 AM EDT - 9 months ago

AngioDynamics, Inc. (ANGO) Q3 2025 Earnings Call Transcript

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

Apr 2, 2025, 6:30 AM EDT - 9 months ago

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

AngioDynamics to Host Virtual Cardiovascular Investor Event

Mar 31, 2025, 8:00 AM EDT - 9 months ago

AngioDynamics to Host Virtual Cardiovascular Investor Event

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

Mar 19, 2025, 8:00 AM EDT - 10 months ago

AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

Mar 10, 2025, 4:30 PM EDT - 10 months ago

AngioDynamics to Present at the Oppenheimer 35th Annual Healthcare MedTech and Services Virtual Conference

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

Jan 30, 2025, 7:30 AM EST - 1 year ago

AngioDynamics Initiates AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

Jan 16, 2025, 5:07 AM EST - 1 year ago

AngioDynamics: Improving Financial Performance And Good Clinical Data Reinvigorate The Shares

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

Jan 13, 2025, 8:00 AM EST - 1 year ago

AngioDynamics Announces Publication of APEX-AV Trial Results in JSCAI

AngioDynamics: A Surgical Approach To Market Growth

Jan 8, 2025, 5:15 PM EST - 1 year ago

AngioDynamics: A Surgical Approach To Market Growth

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

Jan 8, 2025, 11:00 AM EST - 1 year ago

AngioDynamics, Inc. (ANGO) Q2 2025 Earnings Call Transcript

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

Jan 8, 2025, 6:30 AM EST - 1 year ago

AngioDynamics Reports Fiscal Year 2025 Second Quarter Financial Results

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

Jan 6, 2025, 9:26 AM EST - 1 year ago

AngioDynamics to Present at the J.P. Morgan Healthcare Conference

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

Jan 6, 2025, 9:25 AM EST - 1 year ago

AngioDynamics to Host Virtual Event Showcasing the Innovative NanoKnife™ System

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

Dec 19, 2024, 5:00 PM EST - 1 year ago

AngioDynamics to Report Fiscal 2025 Second Quarter Financial Results on January 8, 2025 and Host Virtual NanoKnife Investor Event

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

Dec 9, 2024, 6:00 AM EST - 1 year ago

AngioDynamics Receives FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

Oct 23, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics and University College London Hospital Launch International Multi-Center Study to Assess Long Term Effects of Treatment with The NanoKnife® System

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

Oct 21, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics Announces American Medical Association's CPT® Editorial Panel Grants Category I CPT® for Irreversible Electroporation (IRE) in Prostate and Liver

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

Oct 3, 2024, 10:29 AM EDT - 1 year ago

AngioDynamics, Inc. (ANGO) Q1 2025 Earnings Call Transcript

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

Oct 3, 2024, 10:02 AM EDT - 1 year ago

AngioDynamics, Ingevity, Levi Strauss And Other Big Stocks Moving Lower On Thursday

LEVI NGVT

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

Oct 3, 2024, 6:30 AM EDT - 1 year ago

AngioDynamics Reports Fiscal Year 2025 First Quarter Financial Results

Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings

Oct 3, 2024, 3:37 AM EDT - 1 year ago

Top Wall Street Forecasters Revamp AngioDynamics Price Expectations Ahead Of Q1 Earnings

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

Sep 19, 2024, 4:40 PM EDT - 1 year ago

AngioDynamics Initiates RECOVER-AV Clinical Trial Assessing AlphaVac F18⁸⁵ System in Treatment of Pulmonary Embolism and Long-Term Functional Outcomes

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

Sep 19, 2024, 8:00 AM EDT - 1 year ago

AngioDynamics to Report Fiscal 2025 First Quarter Financial Results on October 3, 2024

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

Sep 3, 2024, 8:30 AM EDT - 1 year ago

AngioDynamics Announces CE Mark Approval in Europe for the Auryon System

AngioDynamics to Participate in Upcoming Investor Conferences

Jul 29, 2024, 4:15 PM EDT - 1 year ago

AngioDynamics to Participate in Upcoming Investor Conferences

AngioDynamics: Lumpy Progress Is Still Progress

Jul 17, 2024, 3:16 PM EDT - 1 year ago

AngioDynamics: Lumpy Progress Is Still Progress

Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance

Jul 16, 2024, 1:51 PM EDT - 1 year ago

Medical Devices Maker AngioDynamics Lays Out Growth Plans, Issues Upbeat Annual Guidance

OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 1 at 12:30 AM
$ANGO RSI: 40.91, MACD: 0.1206 Vol: 0.22, MA20: 13.26, MA50: 12.61 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
RococoReturns
RococoReturns Dec. 25 at 11:43 AM
$ANGO The next leg of valuation movement will likely hinge on how management navigates competing priorities. The market is increasingly intolerant of delays that stretch credibility. Sharper prioritization may be required to avoid execution dilution. Sustainable upside exists, but only alongside disciplined follow‑through.
0 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 7:18 PM
$ANGO surges 30.2% in 6 months — what's driving the momentum? 🚀 🔬 NanoKnife sees 25% revenue growth in prostate cancer with expanding adoption 💉 Med Tech segment now nearly 50% of sales, led by 26% growth in Q1 📈 Thrombectomy revenue jumps 41.2% with aggressive market penetration Discover why ANGO is on the rise 👉 https://www.zacks.com/stock/news/2808804/reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2808804-body-26320&ADID=SYND_STOCKTWITS_TWEET_2_2808804_BODY_26320
1 · Reply
ZacksResearch
ZacksResearch Dec. 24 at 6:18 PM
Still holding $ANGO? Here’s why that call isn’t crazy right now 👀 AngioDynamics continues to benefit from NanoKnife, ongoing clinical milestones, and a balanced portfolio, which are helping counter tariff headwinds and support a hold stance for the time being. Full hold-case breakdown here 👉 https://www.zacks.com/stock/news/2808804/reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2808804-teaser-26288&ADID=SYND_STOCKTWITS_TWEET_2_2808804_TEASER_26288
0 · Reply
Estimize
Estimize Dec. 18 at 11:03 PM
Wall St is expecting -0.10 EPS for $ANGO Q2 [Reporting 01/01 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
Estimize
Estimize Dec. 10 at 11:03 AM
Wall St is expecting -0.10 EPS for $ANGO Q2 [Reporting 01/01 BMO] http://www.estimize.com/intro/ango?chart=historical&metric_name=eps&utm_c
0 · Reply
SuperGreenToday
SuperGreenToday Dec. 9 at 7:14 PM
$ANGO Share Price: $13.38 Contract Selected: Jul 17, 2026 $12.5 Calls Buy Zone: $1.44 – $1.78 Target Zone: $2.41 – $2.94 Potential Upside: 57% ROI Time to Expiration: 219 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
buythedipanddonttrip
buythedipanddonttrip Dec. 5 at 3:51 PM
$ANGO Panagora Asset Management Inc. Sells 138,518 Shares of AngioDynamics, Inc. $ANGO
0 · Reply
Doozio
Doozio Nov. 24 at 6:17 PM
$ANGO Thursday 🐑 low???? 🍿. Bums.
0 · Reply
Doozio
Doozio Nov. 24 at 6:16 PM
$ANGO it can’t be a MNDY 🐑 suck in if all them bums been selling like scuuuured jabronis!
0 · Reply
ZacksResearch
ZacksResearch Nov. 21 at 4:11 PM
$ANGO soars 24.8% YTD — Is NanoKnife the game changer? 🚀 AngioDynamics' NanoKnife is driving growth with over 25% revenue increase in NanoKnife Q1 FY26, bolstered by prostate cancer procedures and a new awareness campaign. With reimbursement catalysts on the horizon, the future looks promising for ANGO. Discover the potential here 👉 https://www.zacks.com/stock/news/2794277/reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2794277-body-22045&ADID=SYND_STOCKTWITS_TWEET_2_2794277_BODY_22045
0 · Reply
ZacksResearch
ZacksResearch Nov. 21 at 3:11 PM
Still holding $ANGO? Here’s why that might not be a bad move. NanoKnife momentum, fresh clinical milestones, and a balanced portfolio are working in its favor — even with those tariff headwinds hanging over the story. Full rundown here 👉 https://www.zacks.com/stock/news/2794277/reasons-to-hold-angiodynamics-stock-in-your-portfolio-for-now?cid=sm-stocktwits-2-2794277-teaser-22027&ADID=SYND_STOCKTWITS_TWEET_2_2794277_TEASER_22027
0 · Reply
Jigajack1
Jigajack1 Nov. 10 at 2:29 PM
$ANGO moon
0 · Reply
Doozio
Doozio Nov. 8 at 8:21 PM
$ANGO chop chop huckleberries 🐒🍌🧠⏰♾️
0 · Reply
Doozio
Doozio Oct. 28 at 1:37 AM
$ANGO up the Roger riding da huckleberries yo go as it spreads on the DLO 🐒🍌🧠⏰♾️
0 · Reply
SexyStockSlayer
SexyStockSlayer Oct. 27 at 11:17 PM
$ANGO still swinging $ANGO Oct 26, 6:20 AM AngioDynamics reports strong Q1 results, raises full-year guidance, and posts 12.2% sales growth, driving reaffirmed Buy rating from H.C. Wainwright. PR today: AngioDynamics to Participate in the UBS Global Healthcare Conference 11/10/2025
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:23 PM
$ANEW $ANF $ANGO $ANIP $ANRO
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 23 at 6:50 PM
$ANGO $ANIP $ANRO 🔥 Cycle Trading Signal plugged into AI 🔥 You lie they lie but Math don't lie 🔥 keep counting 😉
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 23 at 4:56 PM
$ANGO Outstanding article that hits the mark on ANGO's current state. So if you want to refresh your ANGO insights or learn about ANGO from scratch, this is a must read. https://beyondspx.com/quote/ANGO/analysis/angiodynamics-medtech-momentum-fuels-profitable-growth-trajectory-nasdaq-ango
0 · Reply
SexyStockSlayer
SexyStockSlayer Oct. 22 at 8:21 PM
$ANGO 📰Another insider buy on $ANGO SVP, Chief Legal Officer buys 10,000 shares worth $118,100 https://x.com/sexystockslayer/status/1980982792126382519?s=46&t=5HwCsAVewgyd7U6TGAcZ8w
0 · Reply
SocioCobb
SocioCobb Oct. 22 at 3:33 PM
$ANGO
0 · Reply
SuperCoach
SuperCoach Oct. 16 at 12:45 PM
$ANGO https://time.com/collections/best-inventions-2025/7318433/angiodynamics-nanoknife/
0 · Reply